News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Participate in Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA
View HTML
Toggle Summary ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint)
View HTML
Toggle Summary ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare   Conference On-demand
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
-- New Drug Application (NDA )   accepted   for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021   -- --   Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)   for avacopan in
View HTML
Toggle Summary ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
-- Study Showed T reatment with Avacopan   A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group   -- MOUNTAIN VIEW, Calif. , Nov. 06, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Companies have completed the EU regulatory application   for marketing approval of avacopan Regulatory submission based on positive data from the pivotal P hase-III ADVOCATE trial of avacopan ST. GALLEN , Switzerland and MOUNTAIN VIEW, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020
MOUNTAIN VIEW, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020 . ChemoCentryx executive management will host a conference call and
View HTML
Toggle Summary ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at 12 weeks; numerical improvement observed with avacopan treatment in overall study population --
View HTML
Toggle Summary ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif. , Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered
View HTML
Toggle Summary ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
MOUNTAIN VIEW, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30
View HTML